| $337M | ||
| $259M | ||
| $100M | ||
| $79M | ||
| $60M | ||
| $58M |
Buys | $349,800 | 1 | 17 |
Sells | $754,533 | 5 | 83 |
| PAPA JOSEPH C | President and CEO | 1 | $349,800 | 0 | $0 | $349,800 |
| Katkin Keith | director | 0 | $0 | 1 | $49,417 | $-49,417 |
| Zoon Kathryn C | director | 0 | $0 | 1 | $57,300 | $-57,300 |
| White Marvin L | director | 0 | $0 | 1 | $171,015 | $-171,015 |
| Fowler Neal Franklin | director | 0 | $0 | 1 | $204,050 | $-204,050 |
| DeGolyer Donald W | director | 0 | $0 | 1 | $272,750 | $-272,750 |
Emergent BioSolutions Inc., a life sciences company, focuses on the provision of preparedness and response solutions that address accidental, deliberate, and naturally occurring public health threats (PHTs) in the United States. The company's products address PHTs, which include chemical, biological, radiological, nuclear, and explosives; emerging infectious diseases; travel health; and emerging health crises and acute/emergency care. It offers BioThrax, an anthrax vaccine; ACAM2000, a smallpox vaccine; Botulism Antitoxin Heptavalent to treat botulinum disease; vaccinia immune globulin intravenous that addresses complications from smallpox vaccine; raxibacumab for the treatment and prophylaxis of inhalational anthrax; Anthrasil to for inhalational anthrax; reactive skin decontamination lotion kits; and Trobigard, a combination drug-device auto injector product candidate; and Trobigard, a combination drug-device auto injector product candidate. The company also provides NARCAN, a nasal spray for the emergency treatment of known or suspected opioid overdose; Vivotif, an oral vaccine for typhoid fever; and Vaxchora, a single-dose oral vaccine to treat cholera. In addition, it is developing AP003, a Naloxone multidose nasal spray; AP007, a sustained release Nalmefene injection for treatment of opioid use disorder; AV7909, an anthrax vaccine; CGRD-001, a pralidoxime chloride/atropine auto-injector; CHIKV VLP, a chikungunya virus VLP vaccine; COVID-HIG for the treatment of SARS-CoV2; EGRD-001, a diazepam auto-injector; SIAN, an antidote for the initial treatment of acute poisoning of cyanide; and UniFlu, a universal influenza vaccine. Further, the company provides contract development and manufacturing services comprising drug substance and product manufacturing, and packaging, as well as technology transfer, process, and analytical development services. The company was incorporated in 1998 and is headquartered in Gaithersburg, Maryland.
Over the last 12 months, insiders at Emergent BioSolutions Inc. have bought $349,800 and sold $754,533 worth of Emergent BioSolutions Inc. stock.
On average, over the past 5 years, insiders at Emergent BioSolutions Inc. have bought $231,090 and sold $7.23M worth of stock each year.
Highest buying activity among insiders over the last 12 months: PAPA JOSEPH C (President and CEO) — $349,800.
The last purchase of 60,000 shares for transaction amount of $349,800 was made by PAPA JOSEPH C (President and CEO) on 2025‑05‑13.
| 2025-05-23 | Sale | Katkin Keith | director | 7,844 0.0142% | $6.30 | $49,417 | +3.13% | |
| 2025-05-13 | PAPA JOSEPH C | President and CEO | 60,000 0.1096% | $5.83 | $349,800 | +10.88% | ||
| 2025-03-12 | Sale | Fowler Neal Franklin | director | 35,000 0.0611% | $5.83 | $204,050 | -3.01% | |
| 2025-03-12 | Sale | Zoon Kathryn C | director | 10,000 0.0171% | $5.73 | $57,300 | -3.01% | |
| 2024-11-12 | Sale | DeGolyer Donald W | director | 25,000 0.0461% | $10.91 | $272,750 | -37.28% | |
| 2024-11-11 | Sale | White Marvin L | director | 14,287 0.0264% | $11.97 | $171,015 | -42.94% | |
| 2024-06-04 | Sale | Zoon Kathryn C | director | 10,000 0.021% | $6.11 | $61,100 | +47.75% | |
| 2024-05-29 | Sale | Zoon Kathryn C | director | 1,830 0.0035% | $4.61 | $8,436 | +77.05% | |
| 2024-05-21 | Sale | Zoon Kathryn C | director | 1,089 0.0023% | $5.78 | $6,294 | +58.59% | |
| 2023-06-02 | Sale | Zoon Kathryn C | director | 1,830 0.0037% | $8.35 | $15,281 | -67.72% | |
| 2023-05-25 | Sale | Zoon Kathryn C | director | 1,700 0.0035% | $8.38 | $14,246 | -66.99% | |
| 2022-11-25 | Sale | Richard Ronald | director | 1,912 0.0038% | $11.94 | $22,829 | -30.00% | |
| 2022-06-09 | Sale | Zoon Kathryn C | 1,173 0.0023% | $31.52 | $36,973 | -57.24% | ||
| 2022-05-24 | Sale | Zoon Kathryn C | 1,996 0.0043% | $35.53 | $70,918 | -58.06% | ||
| 2021-11-15 | LINDAHL RICHARD S | EVP, Chief Financial Officer | 3,000 0.0055% | $37.46 | $112,380 | -11.87% | ||
| 2021-05-25 | Sale | Zoon Kathryn C | director | 3,139 0.0058% | $56.48 | $177,291 | -17.33% | |
| 2021-03-04 | Sale | Bailey Sue | director | 8,168 0.0156% | $92.37 | $754,478 | -36.39% | |
| 2021-03-01 | Sale | Havey Adam | EVP, Business Operations | 37,279 0.068% | $99.30 | $3.7M | -42.76% | |
| 2021-02-08 | Sale | Kramer Robert | President and CEO | 13,000 0.0237% | $120.03 | $1.56M | -51.36% | |
| 2021-01-21 | Sale | Kramer Robert | President and CEO | 21,900 0.0411% | $110.03 | $2.41M | -44.59% |
| PAPA JOSEPH C | President and CEO | 342500 0.631% | $2.37M | 1 | 0 | |
| DeGolyer Donald W | director | 111100 0.2047% | $769,923.00 | 0 | 1 | |
| Fowler Neal Franklin | director | 101100 0.1863% | $700,623.00 | 0 | 1 | |
| Katkin Keith | director | 86431 0.1592% | $598,966.83 | 0 | 1 | |
| White Marvin L | director | 54092 0.0997% | $374,857.56 | 0 | 2 | |
| Zoon Kathryn C | director | 44482 0.082% | $308,260.26 | 0 | 21 | |
| Intervac, L.L.C. | 10 percent owner | 6136794 11.3063% | $42.53M | 0 | 22 | |
| Biologika, L.L.C. | Member 13(d) group owning >10% | 1399764 2.5789% | $9.7M | 0 | 2 | |
| Michigan Biologic Products, Inc. | Member 13(d) group owning >10% | 1269390 2.3387% | $8.8M | 0 | 39 | |
| El-Hibri Fuad | Chairman | 1123988 2.0708% | $7.79M | 0 | 143 | |
| Abdun-Nabi Daniel | CEO | 142617 0.2628% | $988,335.81 | 2 | 48 | +25.65% |
| Kramer Robert | President and CEO | 139210 0.2565% | $964,725.30 | 0 | 34 | |
| SULLIVAN LOUIS W | director | 42762 0.0788% | $296,340.66 | 0 | 8 | |
| LINDAHL RICHARD S | EVP, Chief Financial Officer | 39919 0.0735% | $276,638.67 | 1 | 0 | <0.0001% |
| Havey Adam | EVP, Business Operations | 38190 0.0704% | $264,656.70 | 1 | 24 | +10.39% |
| JOULWAN GEORGE A | director | 26771 0.0493% | $185,523.03 | 0 | 7 | |
| Labinger Barry | EVP, Biosciences Div. | 25182 0.0464% | $174,511.26 | 0 | 3 | |
| Harsanyi Zsolt | director | 24579 0.0453% | $170,332.47 | 0 | 18 | |
| Bailey Sue | director | 24427 0.045% | $169,279.11 | 0 | 12 | |
| Elsey R Don | Chief Financial Officer | 22199 0.0409% | $153,839.07 | 1 | 9 | <0.0001% |
| Richard Ronald | director | 19837 0.0365% | $137,470.41 | 0 | 25 | |
| Kirk Sean | EVP, Manufacturing & Tech Ops | 12571 0.0232% | $87,117.03 | 0 | 1 | |
| Hauer Jerome M | director | 10188 0.0188% | $70,602.84 | 0 | 16 | |
| Keese Kyle | SVP, Mfg Ops | 9070 0.0167% | $62,855.10 | 0 | 27 | |
| LOCKHART STEPHEN | SVP Product Development | 6980 0.0129% | $48,371.40 | 0 | 3 | |
| Zink Thomas | SVP & CMO | 990 0.0018% | $6,860.70 | 2 | 0 | <0.0001% |
| Esposito Denise | CLO | 500 0.0009% | $3,465.00 | 0 | 2 | |
| Chatfield Steven | EVP, BioSciences | 0 0% | $0 | 0 | 3 | |
| Gibellini Mauro | SVP, Corporate Dev. | 0 0% | $0 | 0 | 1 |
$2,051,022 | 1591 | -12.84% | $48.17M | |
$218,350,131 | 64 | 16.68% | $231.89M | |
$125,860,243 | 57 | -4.48% | $37.59M | |
$129,489,279 | 57 | 26.09% | $554.35M | |
$33,884,330 | 45 | 12.58% | $472.23M | |
$97,642,477 | 41 | -10.58% | $593.18M | |
$102,493,771 | 40 | 22.98% | $999.72M | |
$6,021,989 | 30 | -0.17% | $417.18M | |
$423,174,478 | 29 | -7.58% | $37.04M | |
$32,539,771 | 28 | 33.37% | $228.19M | |
$6,506,230 | 27 | -16.20% | $774.69M | |
$25,034,841 | 20 | 9.38% | $124.2M | |
$1,843,996 | 10 | 22.92% | $972.01M | |
$758,061 | 9 | 60.03% | $167.5M | |
$1,683,154 | 8 | 46.59% | $644.98M | |
Emergent BioSolutions Inc. (EBS) | $179,515 | 7 | 1.51% | $376.15M |
$543,932 | 6 | -22.03% | $571.57M | |
$138,873 | 5 | 1.23% | $64.46M | |
$5,003,136 | 1 | -14.58% | $277.32M |
| Increased Positions | 85 | +45.95% | 7M | +20.38% |
| Decreased Positions | 76 | -41.08% | 6M | -16.52% |
| New Positions | 34 | New | 1M | New |
| Sold Out Positions | 32 | Sold Out | 1M | Sold Out |
| Total Postitions | 194 | +4.86% | 36M | +3.85% |
| Vanguard Group Inc | $16,452.00 | 5.93% | 3.2M | -196,926 | -5.8% | 2024-12-31 |
| American Century Companies Inc | $10,988.00 | 3.96% | 2.14M | +404,667 | +23.35% | 2024-12-31 |
| State Street Corp | $10,094.00 | 3.64% | 1.96M | +52,437 | +2.74% | 2024-12-31 |
| Blackrock, Inc. | $9,435.00 | 3.4% | 1.84M | -87,274 | -4.54% | 2025-03-31 |
| Invesco Ltd. | $7,915.00 | 2.85% | 1.54M | +638,995 | +70.93% | 2024-12-31 |
| Millennium Management Llc | $7,617.00 | 2.74% | 1.48M | +671,947 | +82.96% | 2024-12-31 |
| Marshall Wace, Llp | $6,829.00 | 2.46% | 1.33M | -1M | -46.74% | 2024-12-31 |
| Charles Schwab Investment Management Inc | $6,632.00 | 2.39% | 1.29M | -934,497 | -42.01% | 2024-12-31 |
| Morgan Stanley | $6,307.00 | 2.27% | 1.23M | +3,964 | +0.32% | 2024-12-31 |
| Palisade Capital Management, Lp | $5,868.00 | 2.11% | 1.14M | +202,857 | +21.61% | 2025-03-31 |